Guggenheim on Vera Therapeutics (VERA): 'we would be incremental buyers on any weakness'
Tweet Send to a Friend
Guggenheim analyst Vamil Divan reiterated a Buy rating and $65.00 price target on Vera Therapeutics (NASDAQ: VERA).The analyst comments "Otsuka's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
